Impact of triphenylphosphine as co-ligand on the in vitro antibacterial, anticancer activities and biomolecular binding of Cu(I) and Ag(I) imine complexes Adesola Abimbola Adeleke 1 and Bernard Omondi 2 1 Olabisi Onabanjo University Ago-Iwoye, Nigeria, 2 School of Chemistry and Physics, University of Kwazulu ‐ Natal, South Africa Degenerative diseases still threaten mankind despite several efforts channeled toward their prevention, diagnosis and treatment. In this communication, four isoelectronic Ag(I) and Cu(I) Schiff base complexes (1-4) of the type [M(L)(PPh 3 ) 2 ]X [where M = Ag + or Cu + , L = (E)-N -(2-fluorophenyl)-1-(pyridin-2-yl)methanimine ( fpm ) or (E) -1-(pyridin-2-yl)- N -(p-tolyl)methanimine ( ptm ) and X = NO 3 - ] were synthesized and characterized by various spectroscopic and analytical techniques. The four-coordinates compounds were evaluated for their invitro anticancer activity against non-cancerous human embryonic kidney 293 (HEK293), cervical cancer cell (HELA), breast cancer cell (MDA-MB231) and malignant human melanoma cell (A375) and the result revealed the compound’s significant cytotoxicity on HELA (with EC 50 values between 1.82 ± 1.23 and 10.66 ± 2.87 μM better than cisplatin with EC 50 > 50 μM) and MDA-MB231 (≈2 to 7-fold effective than cisplatin). The invitro antibacterial activity of the synthesized compounds was evaluated against S. aureus , E. coli, S. typhi and P. aeruginosa using the disc diffusion method; the result showed notable antibacterial activity of compounds. The compounds’ interactions with biomolecules were done using UV-visible spectroscopy; the studies showed high binding affinity of the compounds with calf thymus-DNA and moderate affinity to bovine serum albumin. Further, SwissADME was used to approximate the compounds’ drug-like nature, ADME parameters, and pharmacokinetic properties. The data signifies that the compounds could be transported through the gastrointestinal tract, and they do not have the potential to permeate through the brain-blood barrier 1 . All the compounds are not P-glycoprotein substrates, indicating that they are orally available 2 . References
1. Veber, D. F. et al., J. Med. Chem. , 2002. 45(12): p. 2615-2623. 2. Sjögren, E. et al., Eur J Pharm Sci , 2013. 49(4): p. 679-698.
P02
© The Author(s), 2023
Made with FlippingBook Learn more on our blog